|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
 4 Is Cardioprotective after Myocardial Infarction
a Gladstone Institute of Cardiovascular Disease and Department of Pediatrics, University of California San Francisco, San Francisco, California, USA b Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA c Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Key Words: thymosin  4 • cardiac repair • integrin-linked kinase
Address for correspondence: Deepak Srivastava, Gladstone Institute of Cardiovascular Disease, 1650 Owens Street, San Francisco, CA 94158. Voice: 415-734-2716; fax: 415-355-0141. dsrivastava{at}gladstone.ucsf.edu
Heart disease is a leading cause of death in newborns and in adults. Efforts to promote cardiac repair by introduction or recruitment of exogenous stem cells hold promise but typically involve isolation and introduction of autologous or donor progenitor cells. We have found that the G-actin-sequestering peptide thymosin
4 promotes myocardial and endothelial cell migration in the embryonic heart and retains this property in postnatal cardiomyocytes. Survival of embryonic and postnatal cardiomyocytes in culture was also enhanced by thymosin 4. We found that thymosin 4 formed a functional complex with PINCH and integrin-linked kinase (ILK), resulting in activation of the survival kinase Akt/PKB, which was necessary for thymosin 4's effects on cardiomyocytes. After coronary artery ligation in mice, thymosin 4 treatment resulted in upregulation of ILK and Akt activity in the heart, enhanced early myocyte survival, and improved cardiac function. These findings suggest that thymosin 4 promotes cardiomyocyte and endothelial migration, survival, and repair and may be a novel therapeutic target in the setting of acute myocardial damage.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
